The Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management

6-8 November, 2017 / Copenhagen, Denmark

Application deadline is September 15th.

The Summit

At this Summit, 10 selected Patient Entrepreneurs will have the opportunity to engage with Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, as well as venture capitalists


Lyfebulb and Novo Nordisk share a common ambition to stimulate high-impact innovation and to help patient entrepreneurs who have founded start-ups be successful. The Lyfebulb–Novo Nordisk Innovation Summit was built on the idea of the Lyfebulb Entrepreneur Circle, which was established in 2015, and features people who either have diabetes or have a close relative or loved one with the disease. They have created a product and/or a company based on issues encountered because of their personal experiences with diabetes. The first Lyfebulb-Novo Nordisk Innovation Summit took place in December of 2016, and the winner of the Award was Brianna Wolin.

The Innovation Summit will bring together Patient Entrepreneurs with venture capitalists, Lyfebulb founders, Novo Nordisk Device R&D leadership, researchers and engineers, in order to spotlight entrepreneurs’ efforts and ideas, and provide professional discussion, direction, and inspiration. This year the summit will give focus to innovations that disrupt the future of diabetes management.


  • Innovation Award
  • Keynotes
  • Workshops & Discussions
  • Behind the scenes of Novo Nordisk Device R&D

The Award


Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. Our aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes.


Pitch Competition. The pitch competition brings to the stage emerging Patient Entrepreneurs to pitch their invention or idea to Lyfebulb founders, Novo Nordisk R&D device leadership, researchers and engineers, and venture capitalists. Contestants will respond to a round of Q&A by the judging panel. The top three outstanding Patient Entrepreneurs will receive monetary awards to further develop their ideas:

  • 1st Prize: 25,000USD
  • 2nd Prize: 15,000USD
  • 3rd Prize: 10,000USD

National and international recognition:
Visibility of the selected 10 finalists and the winner in particular.

Invitation to the Lyfebulb–Novo Nordisk Innovation Summit 2017 in Copenhagen as one of 10 Finalists.

  • Travel to and from, and accommodation in Copenhagen, Denmark during the Summit.
  • Opportunity to engage with Lyfebulb founders, Novo Nordisk device research leadership, researchers and engineers, and venture capitalists to interact and discuss how together we can disrupt the future of the management of diabetes.

International Judging Panel. The winner will be chosen by a judging panel made up of international representatives from the diabetes community.

Are you the winner of the 2017 Lyfebulb–Novo Nordisk Innovation Award?

Application deadline is September 15th.


Summit & Award Judging Criteria

The Summit is open to Patient Entrepreneurs developing big ideas using consumer, medical devices and healthcare IT that disrupt the future management of diabetes


You are eligible for the 2017 Lyfebulb-Novo Nordisk Innovation Award if:

You work on innovative ideas and concepts for better management of diabetes using consumer or medical devices or healthcare IT (drug only innovations are excluded).

You live with diabetes or have a close relative and/or loved one with diabetes.

You have the aspiration to develop your project and to deliver the benefit to others suffering from the same burden.

You have a registered company for developing and commercializing your idea and concepts that the prize money can be award too.

You can document that there is a sound scientific and medical rationale for the idea.

You have a strong business case behind the idea.

Read our terms and conditions for the full eligibility criteria here.


The judging panel will look for evidence of:

Does the idea have potential to improve the lives of people with type 1 or type 2 diabetes?

In what aspect is the product/service unique in the market (not an altered marketed device) and does it meet other demands as well?

How is the idea truly disruptive for a different future for diabetes management?

Are the innovative and effective technologies scalable?

Ability to meet most of the healthcare related challenges (e.g. funding, regulations, requirements for clinical testing, etc.)

Team behind the project.


November 6, 2017: Afternoon
Pitch presentations to an audience and the judges
November 6, 2017: Evening
Cocktails and seated dinner
November 7, 2017: Morning
Concurrent sessions – deliberation by Judges, and breakout session(s) for participating companies
November 7, 2017: Lunch
Announcement of winners by Kenneth Strømdahl, Senior Vice President, Novo Nordisk Device R&D , and Karin Hehenberger, CEO of Lyfebulb

Achieving More, Together


Lyfebulb is a business focused on bridging patient communities with industry, and providing a strong voice to people living with chronic disease by empowering Patient Entrepreneurs. Our vision is to improve the quality of life of those living with diabetes and other chronic disease.

Lyfebulb was founded in 2014 and is headquartered in New York, NY.

Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.

Headquartered in Denmark, Novo Nordisk employs approximately 42,000 people in 77 countries and markets its products in more than 165 countries.

For More information visit:, Facebook, Twitter, LinkedIn, YouTube


Fill out the form below to the best of your abilities to be considered for the 2017 Lyfebulb-Novo Nordisk Innovation Summit & Award.

Application deadline is September 15th.

  • FacebookTwitterLinkedinOther 
    Add a new row
  • Describe your registered company for developing and commercializing your idea? (Please give evidence of registration)
  • A Patient Entrepreneur is someone who is living with, or is affected by a chronic disease (i.e: relative) and is working on an innovative project to better the management of those living with that chronic disease. Please do not include any personal information about the management of diabetes.)
  • Explain the problem your innovative idea or concept aims to solve and why you think it will empower and disrupt a different future of diabetes management.
  • If awarded the innovation award and monetary prize please describe how you plan to further the advancement of your idea?
  • Guidance for the PDF

    Please attach a 2-page (maximum) Executive Summary of your business, solely non-confidential information that includes the following:

    - Your story and describe your idea
    - Technical explanation of the concept, including an explanation of the technical feasibility.
    - Evidence of how you have you used innovative and effective technologies to scale up your idea
    - Examples of how you have overcome healthcare related challenges in developing your ideas.
    - Business plans, including development and commercial plans, as well as the team behind the project, patent status, funding raised for the project.
  • Accepted file types: pdf.
  • Please upload a short video (120 secs) showcasing your idea and explaining the problem and how it has the potential to disrupt and empower other people living with type 1 or type 2 diabetes for a different future of diabetes management.
  • Please upload a high resolution profile picture (at least 500px x 500px)
  • Lyfebulb Innovation Award Terms and Conditions

    Conditions to Apply

    In order to apply for the Lyfebulb Innovation Award and the Innovation Summit, applicant must fulfil all the bellow conditions:

    (a) The applicant must be working on innovative ideas and concepts for better management of diabetes using consumer or medical devices, or healthcare IT.

    (b) The applicant is living with diabetes or has a close family member and/or loved one living with diabetes.

    (c) The applicant must have established a registered company for developing and commercializing his or her idea, concept, product or service.

    (d) The applicant’s idea, concept, product or service must be original and not include altered or copied products from third parties.

    (e) The applicant's idea, concept, product or services must, to the applicant's knowledge, be free of third party rights, including intellectual property rights.

    (f) Applicant must be 18 years of age or older.

    (g) Participants will be required to sign an agreement with Novo Nordisk to ensure compliance with Novo Nordisk policies.

    U.S. Applicants

    Patients participating in any U.S. government, state, or federally funded medical or prescription benefit programs, including Medicare, Medicaid, Medigap, VA, DOD, and TRICARE, are not eligible to participate. This includes patients participating in a Managed Medicaid plan or who have Medicaid as secondary insurance.

    No Referral or Product Use Requirement. Application imposes no referral or Novo Nordisk product or service use requirement.

    Personal Data. By submitting an application for the Lyfebulb Innovation Award and the Innovation Summit, applicant expressly consents to: (i) the collection, use and retention by Lyfebulb and Novo Nordisk of the applicant’s personal and business information contained in the application for all purposes (including promotion and publicity) related to the Lyfebulb Innovation Award and the Innovation Summit; and (ii) the publication of the applicant’s name and entrepreneurial story on Lyfebulb’s and Novo Nordisk’s websites as well as on their social media channels (Facebook, Twitter, YouTube, Instagram, etc.). Any such information submitted will be transferred to servers located in the United States of America and treated under the laws of the United States of America.
Interests - Select all that apply